John Leite Biography and Net Worth

Chief Commercial Officer, CLIA Business of Veracyte

John Leite is Chief Commercial Officer, CLIA Business at Veracyte. In this role, Dr. Leite leads commercial operations for Veracyte’s diagnostic tests that are performed in the company’s CLIA laboratories. This includes market development, product marketing, reimbursement and sales. Dr. Leite joined Veracyte in September 2022, bringing with him deep diagnostics industry leadership experience. Previously, he served as Chief Business Officer for InterVenn Biosciences, a private-stage diagnostics company, where he was responsible for the company’s commercial, partnership and market access strategy. Prior to that, he held leadership positions at Illumina from 2014 to 2020, where he initially served as Vice President, Oncology, Market Development and Product Development, and then as Vice President, Clinical Business Development. Prior to Illumina, he was Vice President of Commercial Strategy and Market Access at Genoptix Medical Laboratories. Dr. Leite holds a B.S. in Biochemistry from Rutgers University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Pittsburgh School of Medicine. In addition, he completed post-doctoral work as a National Research Service Award Fellow at the California Institute of Technology.

What is John Leite's net worth?: The estimated net worth of John Leite is at least $3.52 million as of December 4th, 2025. Mr. Leite owns 82,113 shares of Veracyte stock worth more than $3,517,721 as of December 13th. This net worth estimate does not reflect any other assets that Mr. Leite may own. Additionally, Mr. Leite receives an annual salary of $1,530,000.00 as Chief Commercial Officer, CLIA Business at Veracyte. Learn More about John Leite's net worth.
How old is John Leite?: Mr. Leite is currently 52 years old. There are 6 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on John Leite's age.
What is John Leite's salary?: As the Chief Commercial Officer, CLIA Business of Veracyte, Inc., Mr. Leite earns $1,530,000.00 per year. The highest earning executive at Veracyte is Mr. Marc A. Stapley, CEO & Director, who commands a salary of $1,550,000.00 per year. Learn More on John Leite's salary.
How do I contact John Leite?: The corporate mailing address for Mr. Leite and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on John Leite's contact information.
Has John Leite been buying or selling shares of Veracyte?: During the last ninety days, John Leite has sold $201,117.78 in shares of Veracyte stock. Most recently, John Leite sold 1,278 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $47.51, for a transaction totalling $60,717.78. Following the completion of the sale, the insider now directly owns 82,113 shares of the company's stock, valued at $3,901,188.63. Learn More on John Leite's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Phillip Febbo (Insider), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Annie Mcguire (SVP), Marc Stapley (CEO), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 152,722 shares worth more than $6,555,695.43. The most recent insider tranaction occured on December, 5th when Director Karin Eastham sold 20,000 shares worth more than $909,000.00. Insiders at Veracyte own 1.4% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 12/5/2025.

John Leite Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2025	Sell	1,278	$47.51	$60,717.78	82,113
11/25/2025	Sell	2,808	$50.00	$140,400.00	86,291
12/3/2024	Sell	1,050	$43.25	$45,412.50	73,810
9/4/2024	Sell	5,479	$29.78	$163,164.62	76,174
7/16/2024	Sell	1,277	$25.00	$31,925.00	82,968

John Leite Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Today's Range

Now: $42.84

$41.55

$43.41

50 Day Range

MA: $40.15

$33.95

$49.38

2 Week Range

Now: $42.84

$22.61

$50.71

Volume

821,560 shs

Average Volume

972,146 shs

Market Capitalization

$3.39 billion

P/E Ratio

112.74

Dividend Yield

N/A

Beta

1.83

John Leite Biography and Net Worth

What is John Leite's net worth?

How old is John Leite?

What is John Leite's salary?

How do I contact John Leite?

Has John Leite been buying or selling shares of Veracyte?

Who are Veracyte's active insiders?

Are insiders buying or selling shares of Veracyte?